Page 112 - Human Use News Today

Ultomiris (ravulizumab), the first and only long-acting C5 complement inhibitor, offers immediate, complete and sustained complement inhibition.

Ultomiris, the generalised myasthenia gravis (gMG) treatment developed by multinational pharmaceutical giant AstraZeneca PLC (LSE:AZN), has been approved...

LONDON (dpa-AFX) - AstraZeneca PLC (AZN.L, AZN) announced Ultomiris has been approved in Europe as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia

Investegate announcements from AstraZeneca PLC, Ultomiris approved in EU for gMG

AstraZeneca Alexions Ultomiris approved in Europe for gMG

The Centre for Covid-19 Situation Administration (CCSA) is considering more measures to promote tourism due to a drop in the number of daily Covid-19 cases.

LONDON (dpa-AFX) - British drug major AstraZeneca Plc (AZN.L, AZN) Wednesday said its Tezspire (tezepelumab) has been approved in the European Union for the treatment of severe asthma.Tezspire

The Centre for Covid-19 Situation Administration (CCSA) is considering more measures to promote tourism due to a drop in the number of daily Covid-19 cases.

The Committee for Medicinal Products for Human Use (CHMP) recommended 12 medicines for approval, including those for rare diseases, osteoporosis and cancer.

Tezspire is a maintenance therapy for patients with no phenotype or biomarker limitations - News - PharmaTimes